PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Positive phase 3 data for Sanofi’s Dupixent

Research showed significant improvements in signs and symptoms of prurigo nodularis.

It has been revealed that, during a trial, nearly three times as many Dupixent patients experienced clinically meaningful reductions in itch and skin lesions at 24 weeks compared to the placebo.

Detailed positive results from the phase 3 prime trial evaluating Dupixent – also known as dupilumab – in adults with uncontrolled prurigo nodularis were presented in a session at the European Academy of Dermatology and Venereology (EADV) 2022 Congress.

In total, 22 scientific abstracts are being presented at the EADV 2022 Congress discussing Dupixent in atopic dermatitis in patients as young as six months – and its investigational use in chronic spontaneous urticaria and bullous pemphigoid – in addition to prurigo nodularis.

The late-breaking data presented at the EADV 2022 Congress are from the randomised, placebo-controlled phase 3 Prime trial, which met its primary and key secondary endpoints. At 24 weeks, among patients treated with Dupixent in the trial, more than three times as many (60%) experienced a clinically meaningful reduction in itch from baseline, the primary endpoint, compared to placebo patients, while nearly three times as many (48%) achieved clear or almost clear skin.

Gil Yosipovitch, Director of the Miami Itch Center, explained: “These positive results from the second of two dupilumab phase 3 trials in prurigo nodularis confirm inhibiting IL-4 and IL-13 can significantly reduce the unrelenting itch and extensive severe skin lesions that often impair patient quality of life.”

He added: “In my practice, relieving itch and clearing skin are often the top priorities for my patients across a range of chronic skin diseases. These data demonstrate dupilumab has the potential to address and manage these debilitating symptoms in another chronic skin disease with underlying type 2 inflammation.”

The impact of uncontrolled prurigo nodularis on quality of life is one of the highest among inflammatory skin diseases and is comparable to other debilitating chronic diseases that can negatively affect mental health, activities of daily living and social interactions.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026